Skip to content

Neuronetics STIM Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

LBR
LB Pharmaceuticals Inc Common StockLBRX
Stereotaxis logo
StereotaxisSTXS
Neuropace, Inc. logo
Neuropace, Inc.NPCE
Myriad Genetics logo
Myriad GeneticsMYGN
LivaNova logo
LivaNovaLIVN

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-59.6%
Enterprise value$162.64M-44.6%
P/S0.6×-1.4×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's accrued liabilities, current?
Neuronetics (STIM) reported accrued liabilities, current of $9.6M in Q1 2026.
How has Neuronetics's accrued liabilities, current changed year-over-year?
Neuronetics's accrued liabilities, current increased by 3.1% year-over-year, from $9.31M to $9.6M.
What is the long-term trend for Neuronetics's accrued liabilities, current?
Over 5 years (2020 to 2025), Neuronetics's accrued liabilities, current has grown at a 11.0% compound annual growth rate (CAGR), from $7.32M to $12.32M.